Finnrick, an independent testing programme, publishes 6 assays for DAHAN Peptide, and all 5 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 5 Aug 2026.
DAHAN Peptide listed by Finnrick as "active". Source: Finnrick, https://www.finnrick.com/vendors/dahan-peptide.
DAHAN Peptide is listed as active.
| Product | Assays | Result |
|---|---|---|
| Tirzepatide | 6 | 5 passed, 0 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from DAHAN Peptide's own website on 2026-08-17. Pages consulted:
DAHAN Peptide is listed as active and we hold 6 Finnrick assays (5 passing, 0 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 6 assays for DAHAN Peptide, and all 5 that it grades met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation). Most recent assay 5 Aug 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Dalian Handom Chemicals HDC Peptides Review, Dankang BioHealth Peptides Review, Darktides Research Peptides Review.